TITLE

Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial

AUTHOR(S)
Dejesus, Edwin; McCarty, Debra; Farthing, Charles F.; Shortino, Denise D.; Grinsztejn, Beatriz; Thomas, Deborah A.; Schrader, Shannon R.; Castillo, Steve A.; Sension, Michael G.; Gough, Kevin; Madison, Sam J.
PUB. DATE
August 2004
SOURCE
Clinical Infectious Diseases;8/1/2004, Vol. 39 Issue 3, p411
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A randomized, double-blind, double-dummy controlled, multicenter trial was conducted that involved 554 antiretroviral-naive human immunodeficiency virus-infected adults (plasma HIV type 1 [HIV-1] RNA level, ⩾400 copies/mL; CD4+ cell count, >100 cells/mm³) and compared a 300-mg once-daily (q.d.) regimen of lamivudine (3TC) versus a 150-mg twice-daily (b.i.d.) regimen of 3TC, combined with zidovudine (300 mg b.i.d.) and efavirenz (600 mg q.d.), during a 48-week period. Treatments were considered equivalent if the 95% confidence interval (CI) for the difference in proportions of patients achieving an HIV-1 RNA level of <400 copies/mL was within the bound of -12% to 12%. At week 48 of the study, an intent-to-treat analysis in which patients with missing data were considered to have experienced treatment failure showed that the 3TC q.d. and 3TC b.i.d. regimens were equivalent (HIV-1 RNA level <400 copies/mL, 178 [64%] of 278 vs. 174 [63%] of 276; treatment difference, 1% [95% CI, -7.1% to 8.9%]; HIV-1 RNA level <50 copies/mL, 165 [59%] of 278 vs. 168 [61%] of 276; treatment difference, 1.7% [95% CI, -9.7% to 6.6%]). Median increase above baseline in CD4+ cell count was similar (q.d. group, +144 cells/mm³; b.i.d. group, +146 cells/mm³), and the incidences of adverse events, disease progression, and HIV-associated conditions were comparable.
ACCESSION #
13920091

 

Related Articles

  • Peroxisome Proliferator-Activated Receptor γ Agonists and the Treatment of HIV-Associated Lipoatrophy: Unraveling the Molecular Mechanism of Their Shortcomings. Hadigan, Colleen // Journal of Infectious Diseases;12/15/2008, Vol. 198 Issue 12, p1729 

    The article discusses the role of specific drug classes and of individual antiretroviral agents. The recognition of metabolic complications associated with the use of antiretroviral therapy (ART) followed close on the introduction and widespread use of potent combination ART for the treatment of...

  • zidovudine (AZT):. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p229 

    A definition of the term "zidovudine," is presented. It refers to a synthetic thymidine that inhibits the growth and development of the human immunodeficiency virus which causes the acquired immunodeficiency syndrome. In addition, it was the first antiretroviral therapy that was approved by the...

  • Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection. van Marle, Guido; Church, Deirdre L.; Nunweiler, Kali D.; Cannon, Kris; Wainberg, Mark A.; Gill, M. John // Retrovirology;2010, Vol. 7, p74 

    Background: The gut-associated lymphoid tissue (GALT) is the largest lymphoid organ infected by human immunodeficiency virus type 1 (HIV-1). It serves as a viral reservoir and host-pathogen interface in infection. This study examined whether different parts of the gut and peripheral blood...

  • Combivir.  // Royal Society of Medicine: Medicines;2002, p169 

    The article presents information on combivir which is a proprietary, prescription-only compound preparation of the agents lamivudine and zidovudine. It can be used in the treatment of HIV infection, and is available as tablets.

  • Invirase.  // Royal Society of Medicine: Medicines;2002, p307 

    The article presents information on invirase. The drug is a proprietary, prescription-only preparation of the antiviral saquinavir (as mesilate). It can be used in the treatment of HIV infection, and is available as capsules.

  • Epivir.  // Royal Society of Medicine: Medicines;2002, p230 

    The article presents information on Epivir, a proprietary, prescription-only preparation of the antiviral lamivudine. It can be used in the treatment of HIV infection, and is available as tablets and as an oral solution.

  • HIV-1 Superinfection in the Antiretroviral Therapy Era: Are Seroconcordant Sexual Partners at Risk? Campbell, Mary S.; Gottlieb, Geoffrey S.; Hawes, Stephen E.; Nickle, David C.; Wong, Kim G.; Deng, Wenjie; Lampinen, Thomas M.; Kiviat, Nancy B.; Mullins, James I. // PLoS ONE;2009, Vol. 4 Issue 5, p1 

    Background: Acquisition of more than one strain of human immunodeficiency virus type 1 (HIV-1) has been reported to occur both during and after primary infection, but the risks and repercussions of dual and superinfection are incompletely understood. In this study, we evaluated a longitudinal...

  • No Evidence for Decay of the Latent Reservoir in HIV-1-Infected Patients Receiving Intensive Enfuvirtide-Containing Antiretroviral Therapy. Gandhi, Rajesh T.; Bosch, Ronald J.; Aga, Evgenia; Albrecht, Mary; Demeter, Lisa M.; Dykes, Carrie; Bastow, Barbara; Para, Michael; Jun Lai; Siliciano, Robert F.; Siliciano, Janet D.; Eron, Joseph J. // Journal of Infectious Diseases;1/15/2010, Vol. 201 Issue 2, p293 

    Human immunodeficiency virus type 1 (HIV-1) persists in a latent reservoir of infected resting memory CD4 cells in patients receiving antiretroviral therapy.We assessed whether multitarget therapy with enfuvirtide, 2 reverse-transcriptase inhibitors, and a ritonavir-boosted protease inhibitor...

  • Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects. Marier, J. F.; Manthos, H.; Kebir, S.; Ferron, S.; DiMarco, M.; Morellu, G.; Tippabhotla, S. K.; Vijan, T.; Singla, A. K.; Garg, M.; Monif, T. // International Journal of Clinical Pharmacology & Therapeutics;2006, Vol. 44 Issue 5, p240 

    Aim: Zidovudine is a synthetic nucleoside analogue of thymidine with activity against the human immunodeficiency virus type 1 (HIV-1). In patients with HIV infections or the acquired immunodeficiency syndrome (AIDS), zidovudine is a first-line therapy that was shown to reduce morbidity,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics